BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nomelcitinib (D-2570) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nomelcitinib (D-2570)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07715175-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261121
DTEND;VALUE=DATE:20261122
SUMMARY:Nomelcitinib (D-2570): Phase 1 readout est. (NCT07715175)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 1.\nStudy: The Study is to Invest
 igate D-2570 in Participants With Different Levels of Kidney Function.\nEs
 timated primary completion: 21 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07715175
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875842-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nomelcitinib (D-2570): Phase 1 readout est. (NCT07875842)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 1.\nStudy: A Phase I Study of the
  Interaction of D-2570 With Other Drugs in Healthy Adults\nEstimated prima
 ry completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nomelcitinib-d-2570#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07875842
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326813-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07326813)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: A Clinical
  Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of M
 oderate to Severe Plaque Psoriasis\nEstimated primary completion: 12 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nomelcitinib-d-
 2570#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07326813
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130604-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07130604)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: Evaluate t
 he Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaqu
 e Psoriasis\nEstimated primary completion: 28 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07130604
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489885-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07489885)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Psoriasis.\nStudy: A Study to
  Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis\
 nEstimated primary completion: August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07489885
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315061-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07315061)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2.\nStudy: A Phase II Study to Ev
 aluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic
  Arthritis\nEstimated primary completion: 15 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07315061
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625891-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07625891)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Vitiligo.\nStudy: Study of D-
 2570 in Subjects With Non-Segmental Vitiligo\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nome
 lcitinib-d-2570#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07625891
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311200-62@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07311200)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Systemic Lupus Erythematosus.
 \nStudy: A Study of D-2570 in Patients With Active Systemic Lupus Erythema
 tosus (SLE)\nEstimated primary completion: 31 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07311200
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
